ORTHOX LIMITED

Their core work

Orthox is a UK medical device company developing FibroFix™ Cartilage, a silk-based implant designed to repair and regenerate damaged cartilage in the knee. Their core innovation is using silk as a scaffold material — a biocompatible, load-bearing structure that supports tissue regrowth in patients with cartilage lesions caused by injury or osteoarthritis. They progressed from a feasibility study in 2019 to a full SME Phase 2 commercialisation project through 2023, indicating an advanced-stage product moving toward clinical and market entry. Their work sits at the intersection of orthopaedic surgery, biomaterials science, and tissue engineering.

What they specialise in

How they've shifted over time

Orthox entered H2020 funding in 2019 with a lean feasibility study (SME Phase 1, €50k) that carried no specific technical keywords — consistent with a concept-validation exercise testing market and technical viability. By 2020, they had secured a substantial SME Phase 2 grant (€2.5M) with a fully articulated technical profile: cartilage repair, osteoarthritis, silk scaffold, knee injury, and tissue regeneration. The trajectory is a straight line from idea to product: there is no pivot, no broadening of scope, and no change in clinical focus — just a deepening commitment to a single well-defined technology.

Orthox is in late-stage product development and likely moving toward CE marking, clinical trials, or commercial launch of FibroFix™ Cartilage — making them a potential licensing, distribution, or clinical partnership target rather than an R&D collaborator.

How they like to work

Orthox used the EU SME Instrument exclusively — a grant scheme designed for single companies, not consortia, which explains their zero-partner record. This is not a reflection of isolationism but of the instrument's structure: SME Phase 1 and Phase 2 are intentionally company-only grants. In practice, this means Orthox has not been tested as a consortium member or leader in a multi-partner setting, and their collaboration profile within EU projects is effectively unknown. Anyone considering them as a partner should evaluate their openness to collaboration through direct conversation rather than H2020 history.

Orthox has no recorded consortium partners in H2020, which is expected given their exclusive use of the single-company SME Instrument. Their collaborative network — clinical partners, suppliers, investors — likely exists but is not visible in CORDIS data.

What sets them apart

Orthox holds a differentiated position in the cartilage repair market by using silk — a natural, biodegradable polymer — as the structural scaffold, distinguishing FibroFix™ from synthetic polymer or collagen-based competitors. Their full SME Instrument track record (Phase 1 + Phase 2) signals that the technology survived independent expert review twice, which is a meaningful quality signal for potential partners or acquirers. For a consortium builder, they bring a near-market orthopaedic device asset and deep domain focus in a high-prevalence condition affecting tens of millions of patients in Europe.

Highlights from their portfolio

• FibroFix Cartilage
  The largest grant (€2.5M, SME Phase 2) and the project that defines Orthox's commercial identity — a full-scale development effort for a silk-based knee implant targeting an estimated 40M+ osteoarthritis patients in Europe.
• FibroFix
  The €50k SME Phase 1 feasibility grant that unlocked the Phase 2 award, demonstrating that the technology concept cleared EU expert validation before significant funding was committed.